Evidence map›Paper›PMID 28314866›Full record

Trial reportMedical science monitor : international medical journal of experimental and clinical research2017

A Clinical Trial Using Attrition Combined with 5-Aminolevulinic Acids Based Photodynamic Therapy in Treating Squamous Cell Carcinoma.

Jianzhong Peng, Weiguo Feng, Xianyan Luo, Tao Wang, Wenzhong Xiang, Yeqin Dai, Jingyu Zhu, Junhui Zheng

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jianzhong PengDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Weiguo FengDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Xianyan LuoDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Tao WangDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Wenzhong XiangDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Yeqin DaiDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Jingyu ZhuDepartment of Urology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Junhui ZhengDepartment of Dermatology, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China (mainland).
Third People's Hospital of Hangzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Squamous cell carcinoma (SCC) is the second most common type of skin cancer, for which non- or mini-invasive treatment is of critical importance. 5-aminolevulinic acids based photodynamic therapy (ALA-PDT) is a mini-invasive approach that causes focal tumor cell injury, apoptosis, and necrosis through light sensitivity. The efficacy of combining ALA-PDT and surgery in treating SCC, however, has not been demonstrated. MATERIAL AND METHODS A total of 60 SCC patients were randomly assigned into attrition plus ALA-PDT group (experimental group) and single ALA-PDT treatment group (control group). Clinical efficacy, recurrence rate, and adverse effects were analyzed in conjunction with H&E staining and immunohistochemistry (IHC) staining for p53 expression. RESULTS The overall effective rate of the experimental group was 73.3%, which was significantly higher than that of the control group (46.7%). The experimental group also had a lower recurrence rate (16.6% versus 30.0%, p<0.05). Similar rates of adverse effects existed between the two groups. After treatment, abnormal cells disappeared, while the p53 positive rate after treatment was elevated in the two groups (p<0.05 comparison of before and after treatment). The experimental group had a higher p53 positive rate compared to the control group (p<0.05). CONCLUSIONS Combined therapy of attrition with ALA-PDT significantly elevated the effective treatment rate and can decrease the recurrence rate with reliable safety in treating SCC, thus ALA-PDT can be used as an optimal plan for SCC treatment.

Indexed as

AgedAminolevulinic AcidApoptosisCarcinoma, Squamous CellCombined Modality TherapyFemaleHumansMaleMiddle AgedNeoplasm Recurrence, LocalPhotochemotherapyPhotosensitizing AgentsSkin NeoplasmsTreatment OutcomeAminolevulinic AcidPhotosensitizing Agents

Identifiers

PMID28314866
PMCPMC5367852
OpenAlexW2596947520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.